Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Follows up the Death of Farah Kassab and Issues Two Decisions and Two Letters to the General Prosecution and the Order of Physicians

 
The Information Office of Deputy Prime Minister Health Minister Ghassan Hasbani issued the following statement:
 
In the context of following up the death of Farah Kassab after she underwent a cosmetic surgery in a specialized hospital in cosmetic surgeries,
 
Health Minister Ghassan Hasbani took the following actions:
 
  1. The issuance of a decision on the prevention of  surgical operations that require a general anesthetic in day hospitals or other cosmetic surgery clinics.
  2. The issuance of a decision on the prevention of  surgical operations that require a general anesthetic in Dr. Nader Saab hospital specialized in cosmetic surgery.
  3. The issuance of a letter to the Public Prosecutor to investigate into the death of Farah Kassab.
  4. The issuance of a letter to the Lebanese Order of Physicians in Beirut to conduct necessary investigations into the death of Farah Kassab, and give the Order a period of two weeks to clarify some technical medical points and answer questions asked by Health Minister concerning the death of the said woman.
 
These steps came to complete the immediate oral decision of Health Minister Ghassan Hasbani to cease operations in the said clinic after the woman's death, and the written decision issued Friday 2 June 2017 which stipulates the following:
 
  1. Surgeries that may cause complications that require intensive care like liposuction and other surgeries shall not performed in places other than specialized hospitals which include an intensive care division that holds a license form Health Ministry in accordance with due process.
  2. The doctor should explain to the patient the risks of the surgery, including the plastic surgery, and ask the patient to sign the Patient Right Form and the informed consent.
    1
    ...
ATC Name B/G Ingredients Dosage Form Price ↑
A02AF02 ACTONORM B Aluminium hydroxide - 220mg/5ml, Magnesium hydroxide - 200mg/5ml, Simethicone - 25mg/5ml Suspension 425,998 L.L
A02BC01 ARAPRIDE G Omeprazole - 20mg 20mg Capsule, hard, gastro-resistant 427,342 L.L
A02BC01 AXIPRON G Omeprazole - 20mg 20mg Capsule 373,358 L.L
A03BA01 ATROPINE G Atropine sulfate - 1mg/ml 1mg/ml Injectable solution 702,149 L.L
A03BA01 ATROPINE SULFATE RENAUDIN G Atropine sulfate - 1mg/ml 0.10% Injectable solution 397,777 L.L
A03BA01 ATROPINE I.V. 0.25 MG. G Atropine - 0.25mg/ml 0.25mg/ml Injectable solution 2,412,129 L.L
A03BA01 ATROPINE G Atropine sulfate - 0.5mg/ml 0.5mg/ml Injectable solution 680,315 L.L
A03BA01 ATROPINE SULFATE RENAUDIN G Atropine sulfate - 0.5mg/ml 0.5mg Injectable solution 385,683 L.L
A03BA01 ATROPINE SULFATEAGUETTANT G Atropine - 0.1mg/ml 0.1mg/ml Injectable solution 7,805,376 L.L
A03BB01 ANTIPAN G Hyoscine N butylbromide - 20mg/ml Injectable solution 355,798 L.L
A03BB01 ANTIPAN G Hyoscine N butylbromide - 20mg/ml Injectable solution 2,557,140 L.L
A03E ACTICARBINE G Activated charcoal - 70mg, Papaverine HCl - 14mg Tablet, coated 311,771 L.L
A04AA01 APO-ONDANSETRON G Ondansetron - 8mg 8mg Tablet 1,491,665 L.L
A04AA05 ALOXI B Palonosetron HCl - 0.25mg/5ml 0.25mg/5ml Injectable solution 3,656,595 L.L
A04AA55 AKYNZEO B Palonosetron - 0.5mg, Netupitant - 300mg Capsule, hard 7,364,372 L.L
A04AD12 APREPITANT BIOGARAN G Aprepitant - 80mg 80mg Capsule 2,164,930 L.L
A04AD12 APREPITANT BIOGARAN 125MG APREPITANT BIOGARAN 80MG G Aprepitant - 125mg, Aprepitant - 80mg 125mg Capsule 3,246,723 L.L
A07EC02 ASACOL B Mesalazine - 400mg 400mg Tablet, enteric coated 5,895,437 L.L
A07EC02 ASACOL B Mesalazine - 800mg 800mg Tablet 6,833,439 L.L
A07EC02 ASACOL B Mesalazine - 500mg 500mg Suppository 1,703,992 L.L
A07EC02 ASACOL B Mesalazine - 1g/100ml 1g/100ml Enema 2,748,158 L.L
A07EC02 ASACOL B Mesalazine - 1600mg 1600mg Tablet, modified release 8,454,523 L.L
A07EC02 ASACOL B Mesalazine - 1600mg 1600mg Tablet, modified release 12,310,378 L.L
A10AB01 ACTRAPID BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable solution 752,552 L.L
A10AB01 ACTRAPID BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable solution 752,552 L.L
A10AB06 APIDRA SOLOSTAR BioTech Insulin glulisine - 100IU/ml 100IU/ml Injectable solution 3,942,834 L.L
A10AB06 APIDRA BioTech Insulin glulisine - 100IU/ml 100IU/ml Injectable solution 2,221,372 L.L
A10BB12 AMARYL B Glimepiride - 1mg 1mg Tablet 231,141 L.L
A10BB12 AMEPRIDE G Glimepiride - 1mg 1mg Tablet 137,072 L.L
A10BB12 AMARYL B Glimepiride - 2mg 2mg Tablet 233,829 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025